Coya Therapeutics maintains a micro-cap valuation on the Nasdaq exchange, with a total market capitalization fluctuating between $100 million and $116 million USD. This valuation reflects current investor sentiment regarding its clinical trial progress, research partnership milestones, cash reserves, and projected future commercialization of its proprietary regulatory T cell therapies.